Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nile Therapeutics has dosed first patient in its Phase Ib, multi-center, open-label, ascending dose clinical study of the company's CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure.
Subscribe to our email newsletter
The primary objectives of the study are to assess the safety and tolerability of intravenous infusions of CD-NP in patients with heart failure. Safety assessments include measurement of blood pressure, heart rate, serum potassium and kidney function as calculated by glomerular filtration rate (GFR). Clinical assessments include urine flow rate, sodium excretion rate and plasma cGMP, a secondary messenger of the target receptor. The trial is expected to enroll up to approximately 35 patients.
Peter Strumph, CEO of Nile, said: “This trial provides us our first opportunity to assess the drug’s activity in heart failure patients, and to further build on our understanding of the molecule’s mechanism of action.”